8-K: Plus Therapeutics Q3: Cash Boost, Nasdaq Compliance, & CNSide Launch

Plus Therapeutics reported increased cash and investments, regained Nasdaq compliance, and launched its CNSide CSF diagnostics platform with national coverage.

Summary

• Cash and investments significantly increased to $16.6 million as of September 30, 2025, up from $6.9 million on June 30, 2025, and $3.6 million on December 31, 2024.
• Regained compliance with Nasdaq listing criteria, including Market Value of Listing Securities and stockholders' equity thresholds.
• Presented positive Phase 1 clinical trial results for REYOBIQ (ReSPECT-LM) demonstrating feasibility, favorable safety, and promising efficacy for leptomeningeal metastases (LM).
• Expanded commercial readiness for the CNSide CSF diagnostics platform, appointing new leadership and securing the first national coverage agreement with UnitedHealthcare, effective September 15, 2025, covering over 51 million people.
• Received successful CLIA accreditation and certification for the Houston, Texas laboratory, enabling state licensing, commercial payor coverage, and access to Medicare/Medicaid.
• CNSide CSF assay platform results presented at the 2025 SNO/ASCO CNS Metastases Conference showed its ability to quantify LM over time and monitor changes in targetable mutations.
• CNSide Diagnostics launched commercially in Texas in August 2025, initially targeting National Cancer Institute Designated Cancer Centers.
• Recognized $1.4 million in grant revenue for Q3 2025, compared to $1.5 million in Q3 2024, from the CPRIT grant for REYOBIQ development.
• Total operating loss for Q3 2025 was $4.5 million, an increase from $3.8 million in Q3 2024, primarily due to higher compensation expense and professional fees.
• Net loss for Q3 2025 was $4.4 million, or $0.04 per share, compared to a net loss of $2.9 million, or $0.37 per share, for Q3 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant operational achievements including positive clinical trial data, a major commercial launch with national coverage, and regaining Nasdaq compliance. The substantial increase in cash and investments also provides a strong financial footing. While losses increased, this is somewhat expected for a clinical-stage company making significant R&D and commercialization investments.

Positives

• Cash and investments balance significantly increased to $16.6 million, providing a stronger financial position.
• Regained full compliance with Nasdaq listing criteria, ensuring continued market access and investor confidence.
• Positive Phase 1 clinical trial results for REYOBIQ in leptomeningeal metastases (LM) indicate a favorable safety profile and promising efficacy signal.
• Secured a national coverage agreement with UnitedHealthcare for CNSide, effective September 15, 2025, expanding access to over 51 million people.
• Achieved CLIA accreditation and certification for the Houston laboratory, a critical step for commercialization and broader payor coverage for CNSide.
• Commercial launch of CNSide Diagnostics in Texas in August 2025 marks a significant step towards revenue generation.
• Received an additional $1.9 million advance payment from CPRIT, contributing to non-dilutive funding for therapeutic development.

Negatives

• Total operating loss increased to $4.5 million in Q3 2025 from $3.8 million in Q3 2024, driven by higher compensation and professional fees.
• Net loss increased to $4.4 million in Q3 2025 from $2.9 million in Q3 2024, although net loss per share decreased due to a higher share count.

Risks

• Ability to maintain the listing of common stock on Nasdaq.
• Risks related to a halt in trading or delisting of common stock on Nasdaq.
• The early stage of product candidates and therapies.
• Uncertainties relating to the clinical trials of product candidates and therapies.
• Liquidity and capital resources and the ability to raise additional cash.
• The outcome of partnering/licensing efforts.
• Risks associated with laws or regulatory requirements applicable to the company.
• Market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field.
• Ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms.
• Challenges associated with radiotherapeutic manufacturing, production, and distribution capabilities.
• Material security breach or cybersecurity attack affecting operations or property.

Future Outlook

Management plans to build on momentum in Q4 by expanding the commercial team and footprint for CNSide, seeking to clarify the clinical development and pivotal plan for REYOBIQ with the FDA, and bolstering the company's financial position in the capital markets.

Management Comments

• "Our team continues to execute solidly across the three most important business verticals: diagnostics, therapeutics, and capital structure."
• "In the fourth quarter, we plan to build on growing momentum in these three areas as we expand our commercial team and footprint for CNSide, seek to clarify our clinical development and pivotal plan for REYOBIQ with the FDA, and bolster our financial position in the capital markets."

Industry Context

Plus Therapeutics operates in the highly specialized and critical field of central nervous system (CNS) cancers, focusing on targeted radiotherapeutics and advanced diagnostics. The commercial launch of CNSide and positive clinical data for REYOBIQ position the company to address significant unmet needs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), areas where treatment options are limited. The national coverage agreement for CNSide with UnitedHealthcare is a significant step in gaining market penetration for a novel diagnostic in a competitive and rapidly evolving oncology landscape.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from regained Nasdaq compliance, strengthened cash position, positive clinical data, and commercial progress, potentially leading to increased share value.
• Patients: Potential for new diagnostic tools (CNSide) and therapeutic options (REYOBIQ) for difficult-to-treat CNS cancers.
• Employees: Expansion of commercial team and new hires for CNSide indicate growth and job opportunities.
• Healthcare Providers: CNSide offers a new tool for quantifying LM and monitoring treatment, potentially improving patient management.
• UnitedHealthcare Members: Gain coverage for the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test.

Next Steps

• Expand the commercial team and footprint for the CNSide CSF diagnostics platform.
• Seek clarification from the FDA regarding the clinical development and pivotal plan for REYOBIQ.
• Bolster the company's financial position in the capital markets.

Key Dates

Recommendation

Plus Therapeutics has demonstrated significant operational progress with positive clinical trial results for REYOBIQ and a successful commercial launch of CNSide, including a national coverage agreement. The company has also substantially improved its cash position and regained Nasdaq compliance, mitigating immediate financial and listing risks. However, it remains a clinical-stage company with ongoing losses and future capital needs for continued development and commercialization. The positive developments are balanced by the inherent risks of drug development and market penetration, warranting a 'hold' recommendation for investors to observe further progress and execution.

Keywords

Plus Therapeutics, PSTV, Q3 2025, Financial Results, Radiotherapeutics, CNS Cancers, REYOBIQ, Leptomeningeal Metastases, CNSide, CSF Diagnostics, UnitedHealthcare, Nasdaq Compliance, Clinical Trials, Biotechnology, Oncology